|
1
|
Mellman I, Coukos G and Dranoff G: Cancer
immunotherapy comes of age. Nature. 480:480–489. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Butte MJ, Keir ME, Phamduy TB, Sharpe AH
and Freeman GJ: Programmed death-1 ligand 1 interacts specifically
with the B7-1 costimulatory molecule to inhibit T cell responses.
Immunity. 27:111–122. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zou W, Wolchok JD and Chen L: PD-L1
(B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms,
response biomarkers, and combinations. Sci Transl Med.
8:328rv42016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Topalian SL, Sznol M, McDermott DF, Kluger
HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB,
Powderly JD, et al: Survival, durable tumor remission, and
long-term safety in patients with advanced melanoma receiving
nivolumab. J Clin Oncol. 32:1020–1030. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Robert C, Schachter J, Long GV, Arance A,
Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, et al:
Pembrolizumab versus Ipilimumab in advanced melanoma. N Engl J Med.
372:2521–2532. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Larkin J, Chiarion-Sileni V, Gonzalez R,
Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M,
Rutkowski P, et al: Combined nivolumab and Ipilimumab or
Monotherapy in untreated melanoma. N Engl J Med. 373:23–34. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Robert C, Long GV, Brady B, Dutriaux C,
Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C,
Kalinka-Warzocha E, et al: Nivolumab in previously untreated
melanoma without BRAF mutation. N Engl J Med. 372:320–330. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Borghaei H, Paz-Ares L, Horn L, Spigel DR,
Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al:
Nivolumab versus Docetaxel in advanced nonsquamous non-small-cell
lung cancer. N Engl J Med. 373:1627–1639. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Brahmer J, Reckamp KL, Baas P, Crino L,
Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE,
Holgado E, et al: Nivolumab versus Docetaxel in advanced
squamous-cell non-small-cell lung cancer. N Engl J Med.
373:123–135. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Garon EB, Rizvi NA, Hui R, Leighl N,
Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L,
et al: Pembrolizumab for the treatment of non-small-cell lung
cancer. N Engl J Med. 372:2018–2028. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Motzer RJ, Escudier B, McDermott DF,
George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G,
Plimack ER, et al: Nivolumab versus Everolimus in advanced
renal-cell carcinoma. N Engl J Med. 373:1803–1813. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ansell SM, Lesokhin AM, Borrello I,
Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry
D, Freeman GJ, et al: PD-1 blockade with nivolumab in relapsed or
refractory Hodgkin's lymphoma. N Engl J Med. 372:311–319. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Powles T, Eder JP, Fine GD, Braiteh FS,
Loriot Y, Cruz C, Bellmunt J, Burris HA, Petrylak DP, Teng SL, et
al: MPDL3280A (anti-PD-L1) treatment leads to clinical activity in
metastatic bladder cancer. Nature. 515:558–562. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rittmeyer A, Barlesi F, Waterkamp D, Park
K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols
MC, et al: Atezolizumab versus docetaxel in patients with
previously treated non-small-cell lung cancer (OAK): A phase 3,
open-label, multicentre randomised controlled trial. Lancet.
389:255–265. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
McDermott DF, Sosman JA, Sznol M, Massard
C, Gordon MS, Hamid O, Powderly JD, Infante JR, Fasso M, Wang YV,
et al: Atezolizumab, an Anti-programmed Death-Ligand 1 antibody, in
metastatic renal cell carcinoma: Long-term safety, clinical
activity, and immune correlates from a phase Ia study. J Clin
Oncol. 34:833–842. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Topalian SL, Hodi FS, Brahmer JR,
Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD,
Sosman JA, Atkins MB, et al: Safety, activity, and immune
correlates of anti-PD-1 antibody in cancer. N Engl J Med.
366:2443–2454. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fehrenbacher L, Spira A, Ballinger M,
Kowanetz M, Vansteenkiste J, Mazieres J, Park K, Smith D,
Artal-Cortes A, Lewanski C, et al: Atezolizumab versus docetaxel
for patients with previously treated non-small-cell lung cancer
(POPLAR): A multicentre, open-label, phase 2 randomised controlled
trial. Lancet. 387:1837–1846. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Patel SP and Kurzrock R: PD-L1 expression
as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther.
14:847–856. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
McLaughlin J, Han G, Schalper KA,
Carvajal-Hausdorf D, Pelekanou V, Rehman J, Velcheti V, Herbst R,
LoRusso P and Rimm DL: Quantitative assessment of the heterogeneity
of PD-L1 expression in non-small-cell lung cancer. JAMA Oncol.
2:46–54. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Daud AI, Wolchok JD, Robert C, Hwu WJ,
Weber JS, Ribas A, Hodi FS, Joshua AM, Kefford R, Hersey P, et al:
Programmed Death-Ligand 1 expression and response to the
anti-programmed Death 1 antibody pembrolizumab in melanoma. J Clin
Oncol. 34:4102–4109. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Weber JS, Kudchadkar RR, Yu B, Gallenstein
D, Horak CE, Inzunza HD, Zhao X, Martinez AJ, Wang W, Gibney G, et
al: Safety, efficacy, and biomarkers of nivolumab with vaccine in
ipilimumab-refractory or -naive melanoma. J Clin Oncol.
31:4311–4318. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Topalian SL, Taube JM, Anders RA and
Pardoll DM: Mechanism-driven biomarkers to guide immune checkpoint
blockade in cancer therapy. Nat Rev Cancer. 16:275–287. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zou W: Immunosuppressive networks in the
tumour environment and their therapeutic relevance. Nat Rev Cancer.
5:263–274. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Greenwald RJ, Freeman GJ and Sharpe AH:
The B7 family revisited. Annu Rev Immunol. 23:515–548. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Keir ME, Butte MJ, Freeman GJ and Sharpe
AH: PD-1 and its ligands in tolerance and immunity. Annu Rev
Immunol. 26:677–704. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Freeman GJ: Structures of PD-1 with its
ligands: Sideways and dancing cheek to cheek. Proc Natl Acad Sci
USA. 105:10275–10276. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chemnitz JM, Parry RV, Nichols KE, June CH
and Riley JL: SHP-1 and SHP-2 associate with immunoreceptor
tyrosine-based switch motif of programmed death 1 upon primary
human T cell stimulation, but only receptor ligation prevents T
cell activation. J Immunol. 173:945–954. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Reck M, Rodriguez-Abreu D, Robinson AG,
Hui R, Csoszi T, Fulop A, Gottfried M, Peled N, Tafreshi A, Cuffe
S, et al: Pembrolizumab versus chemotherapy for PD-L1-positive
non-small-cell lung cancer. N Engl J Med. 375:1823–1833. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Weber JS, D'Angelo SP, Minor D, Hodi FS,
Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH Jr, Lao CD,
et al: Nivolumab versus chemotherapy in patients with advanced
melanoma who progressed after anti-CTLA-4 treatment (CheckMate
037): A randomised, controlled, open-label, phase 3 trial. Lancet
Oncol. 16:375–384. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Rizvi NA, Mazieres J, Planchard D,
Stinchcombe TE, Dy GK, Antonia SJ, Horn L, Lena H, Minenza E,
Mennecier B, et al: Activity and safety of nivolumab, an anti-PD-1
immune checkpoint inhibitor, for patients with advanced, refractory
squamous non-small-cell lung cancer (CheckMate 063): A phase 2,
single-arm trial. Lancet Oncol. 16:257–265. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ferris RL, Blumenschein G Jr, Fayette J,
Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE,
Even C, et al: Nivolumab for recurrent squamous-cell carcinoma of
the head and neck. N Engl J Med. 375:1856–1867. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Carbone DP, Reck M, Paz-Ares L, Creelan B,
Horn L, Steins M, Felip E, van den Heuvel MM, Ciuleanu TE, Badin F,
et al: First-line nivolumab in stage IV or recurrent non-small-cell
lung cancer. N Engl J Med. 376:2415–2426. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hellmann MD, Ciuleanu TE, Pluzanski A, Lee
JS, Otterson GA, Audigier-Valette C, Minenza E, Linardou H, Burgers
S, Salman P, et al: Nivolumab plus Ipilimumab in lung cancer with a
high tumor mutational burden. N Engl J Med. 378:2093–2104. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hellmann MD, Paz-Ares L, Bernabe Caro R,
Zurawski B, Kim SW, Carcereny Costa E, Park K, Alexandru A,
Lupinacci L, de la Mora Jimenez E, et al: Nivolumab plus Ipilimumab
in advanced non-small-cell lung cancer. N Engl J Med.
381:2020–2031. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Herbst RS, Baas P, Kim DW, Felip E,
Perez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, et al:
Pembrolizumab versus docetaxel for previously treated,
PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010):
A randomised controlled trial. Lancet. 387:1540–1550. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Eggermont AMM, Blank CU, Mandala M, Long
GV, Atkinson V, Dalle S, Haydon A, Lichinitser M, Khattak A,
Carlino MS, et al: Adjuvant pembrolizumab versus placebo in
resected stage III melanoma. N Engl J Med. 378:1789–1801. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho
BC, Turna HZ, Castro G Jr, Srimuninnimit V, Laktionov KK,
Bondarenko I, et al: Pembrolizumab versus chemotherapy for
previously untreated, PD-L1-expressing, locally advanced or
metastatic non-small-cell lung cancer (KEYNOTE-042): A randomised,
open-label, controlled, phase 3 trial. Lancet. 393:1819–1830. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Rosenberg JE, Hoffman-Censits J, Powles T,
van der Heijden MS, Balar AV, Necchi A, Dawson N, O'Donnell PH,
Balmanoukian A, Loriot Y, et al: Atezolizumab in patients with
locally advanced and metastatic urothelial carcinoma who have
progressed following treatment with platinum-based chemotherapy: A
single-arm, multicentre, phase 2 trial. Lancet. 387:1909–1920.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Balar AV, Galsky MD, Rosenberg JE, Powles
T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J,
Perez- Gracia JL, et al: Atezolizumab as first-line treatment in
cisplatin-ineligible patients with locally advanced and metastatic
urothelial carcinoma: A single-arm, multicentre, phase 2 trial.
Lancet. 389:67–76. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Petrylak DP, Powles T, Bellmunt J, Braiteh
F, Loriot Y, Morales-Barrera R, Burris HA, Kim JW, Ding B, Kaiser
C, et al: Atezolizumab (MPDL3280A) monotherapy for patients with
metastatic urothelial cancer: Long-term outcomes from a phase 1
study. JAMA Oncol. 4:537–544. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Socinski MA, Jotte RM, Cappuzzo F, Orlandi
F, Stroyakovskiy D, Nogami N, Rodriguez-Abreu D, Moro-Sibilot D,
Thomas CA, Barlesi F, et al: Atezolizumab for first-line treatment
of metastatic Nonsquamous NSCLC. N Engl J Med. 378:2288–2301. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Powles T, O'Donnell PH, Massard C, Arkenau
HT, Friedlander TW, Hoimes CJ, Lee JL, Ong M, Sridhar SS, Vogelzang
NJ, et al: Efficacy and safety of durvalumab in locally advanced or
metastatic urothelial carcinoma: Updated results from a phase 1/2
open-label study. JAMA Oncol. 3:e1724112017. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Taube JM, Klein A, Brahmer JR, Xu H, Pan
X, Kim JH, Chen L, Pardoll DM, Topalian SL and Anders RA:
Association of PD-1, PD-1 ligands, and other features of the tumor
immune microenvironment with response to anti-PD-1 therapy. Clin
Cancer Res. 20:5064–5074. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Chen G, Huang AC, Zhang W, Zhang G, Wu M,
Xu W, Yu Z, Yang J, Wang B, Sun H, et al: Exosomal PD-L1
contributes to immunosuppression and is associated with anti-PD-1
response. Nature. 560:382–386. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Okuma Y, Wakui H, Utsumi H, Sagawa Y,
Hosomi Y, Kuwano K and Homma S: Soluble programmed cell death
ligand 1 as a novel biomarker for nivolumab therapy for
non-small-cell lung cancer. Clin Lung Cancer. 19:410–417.e1. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Ritprajak P and Azuma M: Intrinsic and
extrinsic control of expression of the immunoregulatory molecule
PD-L1 in epithelial cells and squamous cell carcinoma. Oral Oncol.
51:221–228. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ,
Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al:
Safety and activity of anti-PD-L1 antibody in patients with
advanced cancer. N Engl J Med. 366:2455–2465. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
You W, Li L, Sun D, Liu X, Xia Z, Xue S,
Chen B, Qin H, Ai J and Jiang H: Farnesoid X receptor constructs an
immunosuppressive microenvironment and sensitizes
FXRhigh PD-L1low NSCLC to Anti-PD-1
immunotherapy. Cancer Immunol Res. 7:990–1000. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Ratcliffe MJ, Sharpe A, Barker C, Scorer P
and Walker J: Abstract LB-094: A comparative study of PD-L1
diagnostic assays and the classification of patients as PD-L1
positive and PD-L1 negative. Cancer Res. 76 (14
Suppl):LB-094-LB-094. 2016.
|
|
51
|
Fujimoto D, Yamashita D, Fukuoka J,
Kitamura Y, Hosoya K, Kawachi H, Sato Y, Nagata K, Nakagawa A,
Tachikawa R, et al: Comparison of PD-L1 assays in non-small cell
lung cancer: 22C3 pharmDx and SP263. Anticancer Res. 38:6891–6895.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Lim JS, Sundar R, Chenard-Poirier M, Lopez
J and Yap TA: Emerging biomarkers for PD-1 pathway cancer therapy.
Biomark Med. 11:53–67. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Noman MZ and Chouaib S: Targeting hypoxia
at the forefront of anticancer immune responses. Oncoimmunology.
3:e9544632014. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Gowrishankar K, Gunatilake D, Gallagher
SJ, Tiffen J, Rizos H and Hersey P: Inducible but not constitutive
expression of PD-L1 in human melanoma cells is dependent on
activation of NF-κB. PLoS One. 10:e01234102015. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Liu J, Hamrouni A, Wolowiec D, Coiteux V,
Kuliczkowski K, Hetuin D, Saudemont A and Quesnel B: Plasma cells
from multiple myeloma patients express B7-H1 (PD-L1) and increase
expression after stimulation with IFN-{gamma} and TLR ligands via a
MyD88-, TRAF6-, and MEK-dependent pathway. Blood. 110:296–304.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Lee SJ, Jang BC, Lee SW, Yang YI, Suh SI,
Park YM, Oh S, Shin JG, Yao S, Chen L, et al: Interferon regulatory
factor-1 is prerequisite to the constitutive expression and
IFN-gamma-induced upregulation of B7-H1 (CD274). FEBS Lett.
580:755–762. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Kondo A, Yamashita T, Tamura H, Zhao W,
Tsuji T, Shimizu M, Shinya E, Takahashi H, Tamada K, Chen L, et al:
Interferon-gamma and tumor necrosis factor-alpha induce an
immunoinhibitory molecule, B7-H1, via nuclear factor-kappaB
activation in blasts in myelodysplastic syndromes. Blood.
116:1124–1131. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Jin YH, Hou W, Kang HS, Koh CS and Kim BS:
The role of interleukin-6 in the expression of PD-1 and PDL-1 on
central nervous system cells following infection with Theiler's
murine encephalomyelitis virus. J Virol. 87:11538–11551. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Xiong HY, Ma TT, Wu BT, Lin Y and Tu ZG:
IL-12 regulates B7-H1 expression in ovarian cancer-associated
macrophages by effects on NF-κB signalling. Asian Pac J Cancer
Prev. 15:5767–5772. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Akbay EA, Koyama S, Carretero J, Altabef
A, Tchaicha JH, Christensen CL, Mikse OR, Cherniack AD, Beauchamp
EM, Pugh TJ, et al: Activation of the PD-1 pathway contributes to
immune escape in EGFR-driven lung tumors. Cancer Discov.
3:1355–1363. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Hecht M, Buttner-Herold M,
Erlenbach-Wunsch K, Haderlein M, Croner R, Grutzmann R, Hartmann A,
Fietkau R and Distel LV: PD-L1 is upregulated by radiochemotherapy
in rectal adenocarcinoma patients and associated with a favourable
prognosis. Eur J Cancer. 65:52–60. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Katsuya Y, Horinouchi H, Asao T, Kitahara
S, Goto Y, Kanda S, Fujiwara Y, Nokihara H, Yamamoto N, Watanabe S,
et al: Expression of programmed death 1 (PD-1) and its ligand
(PD-L1) in thymic epithelial tumors: Impact on treatment efficacy
and alteration in expression after chemotherapy. Lung Cancer.
99:4–10. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Takamori S, Takada K, Tagawa T, Toyokawa
G, Hirai F, Yamashita N, Okamoto T, Oki E, Yoshizumi T, Oda Y, et
al: Differences in PD-L1 expression on tumor and immune cells
between lung metastases and corresponding primary tumors. Surg
Oncol. 27:637–641. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Kandoth C, McLellan MD, Vandin F, Ye K,
Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyczalkowski MA, et al:
Mutational landscape and significance across 12 major cancer types.
Nature. 502:333–339. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Alexandrov LB, Nik-Zainal S, Wedge DC,
Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A,
Borresen-Dale AL, et al: Signatures of mutational processes in
human cancer. Nature. 500:415–421. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Herbst RS, Soria JC, Kowanetz M, Fine GD,
Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger
SN, et al: Predictive correlates of response to the anti-PD-L1
antibody MPDL3280A in cancer patients. Nature. 515:563–567. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Rizvi NA, Hellmann MD, Snyder A, Kvistborg
P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, et al: Cancer
immunology. Mutational landscape determines sensitivity to PD-1
blockade in non-small cell lung cancer. Science. 348:124–128. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Forde PM, Chaft JE, Smith KN, Anagnostou
V, Cottrell TR, Hellmann MD, Zahurak M, Yang SC, Jones DR,
Broderick S, et al: Neoadjuvant PD-1 blockade in resectable lung
cancer. N Engl J Med. 378:1976–1986. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Wang Z, Duan J, Cai S, Han M, Dong H, Zhao
J, Zhu B, Wang S, Zhuo M, Sun J, et al: Assessment of blood tumor
mutational burden as a potential biomarker for immunotherapy in
patients with non-small cell lung cancer with use of a
next-generation sequencing cancer gene panel. JAMA Oncol.
5:696–702. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Lipson EJ, Sharfman WH, Drake CG, Wollner
I, Taube JM, Anders RA, Xu H, Yao S, Pons A, Chen L, et al: Durable
cancer regression off-treatment and effective reinduction therapy
with an anti-PD-1 antibody. Clin Cancer Res. 19:462–468. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Li GM: Mechanisms and functions of DNA
mismatch repair. Cell Res. 18:85–98. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Le DT, Uram JN, Wang H, Bartlett BR,
Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et
al: PD-1 blockade in tumors with mismatch-repair deficiency. N Engl
J Med. 372:2509–2520. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Le DT, Durham JN, Smith KN, Wang H,
Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, et
al: Mismatch repair deficiency predicts response of solid tumors to
PD-1 blockade. Science. 357:409–413. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Schumacher TN and Schreiber RD:
Neoantigens in cancer immunotherapy. Science. 348:69–74. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
75
|
McGranahan N, Furness AJ, Rosenthal R,
Ramskov S, Lyngaa R, Saini SK, Jamal-Hanjani M, Wilson GA, Birkbak
NJ, Hiley CT, et al: Clonal neoantigens elicit T cell
immunoreactivity and sensitivity to immune checkpoint blockade.
Science. 351:1463–1469. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Van Allen EM, Golay HG, Liu Y, Koyama S,
Wong K, Taylor-Weiner A, Giannakis M, Harden M, Rojas-Rudilla V,
Chevalier A, et al: Long-term benefit of PD-L1 blockade in lung
cancer associated with JAK3 activation. Cancer Immunol Res.
3:855–863. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Azuma K, Ota K, Kawahara A, Hattori S,
Iwama E, Harada T, Matsumoto K, Takayama K, Takamori S, Kage M, et
al: Association of PD-L1 overexpression with activating EGFR
mutations in surgically resected nonsmall-cell lung cancer. Ann
Oncol. 25:1935–1940. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Parsa AT, Waldron JS, Panner A, Crane CA,
Parney IF, Barry JJ, Cachola KE, Murray JC, Tihan T, Jensen MC, et
al: Loss of tumor suppressor PTEN function increases B7-H1
expression and immunoresistance in glioma. Nat Med. 13:84–88. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Marzec M, Zhang Q, Goradia A, Raghunath
PN, Liu X, Paessler M, Wang HY, Wysocka M, Cheng M, Ruggeri BA, et
al: Oncogenic kinase NPM/ALK induces through STAT3 expression of
immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci
USA. 105:20852–20857. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Yadav M, Jhunjhunwala S, Phung QT,
Lupardus P, Tanguay J, Bumbaca S, Franci C, Cheung TK, Fritsche J,
Weinschenk T, et al: Predicting immunogenic tumour mutations by
combining mass spectrometry and exome sequencing. Nature.
515:572–576. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Zaretsky JM, Garcia-Diaz A, Shin DS,
Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Torrejon DY,
Abril-Rodriguez G, Sandoval S, Barthly L, et al: Mutations
associated with acquired resistance to PD-1 blockade in melanoma. N
Engl J Med. 375:819–829. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Skoulidis F, Goldberg ME, Greenawalt DM,
Hellmann MD, Awad MM, Gainor JF, Schrock AB, Hartmaier RJ, Trabucco
SE, Gay L, et al: STK11/LKB1 mutations and PD-1 inhibitor
resistance in KRAS-mutant lung adenocarcinoma. Cancer Discov.
8:822–835. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Chen F, Zhuang X, Lin L, Yu P, Wang Y, Shi
Y, Hu G and Sun Y: New horizons in tumor microenvironment biology:
Challenges and opportunities. BMC Med. 13:452015. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Mantovani A, Allavena P, Sica A and
Balkwill F: Cancer-related inflammation. Nature. 454:436–444. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Yang L, Pang Y and Moses HL: TGF-beta and
immune cells: An important regulatory axis in the tumor
microenvironment and progression. Trends Immunol. 31:220–227. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Pauken KE and Wherry EJ: Overcoming T cell
exhaustion in infection and cancer. Trends Immunol. 36:265–276.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Li HY, McSharry M, Bullock B, Nguyen TT,
Kwak J, Poczobutt JM, Sippel TR, Heasley LE, Weiser-Evans MC,
Clambey ET, et al: The tumor microenvironment regulates sensitivity
of murine lung tumors to PD-1/PD-L1 antibody blockade. Cancer
Immunol Res. 5:767–777. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Smyth MJ, Ngiow SF, Ribas A and Teng MW:
Combination cancer immunotherapies tailored to the tumour
microenvironment. Nat Rev Clin Oncol. 13:143–158. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Tumeh PC, Harview CL, Yearley JH, Shintaku
IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu
V, et al: PD-1 blockade induces responses by inhibiting adaptive
immune resistance. Nature. 515:568–571. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Chen PL, Roh W, Reuben A, Cooper ZA,
Spencer CN, Prieto PA, Miller JP, Bassett RL, Gopalakrishnan V,
Wani K, et al: Analysis of immune signatures in longitudinal tumor
samples yields insight into biomarkers of response and mechanisms
of resistance to immune checkpoint blockade. Cancer Discov.
6:827–837. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Daud AI, Loo K, Pauli ML,
Sanchez-Rodriguez R, Sandoval PM, Taravati K, Tsai K, Nosrati A,
Nardo L, Alvarado MD, et al: Tumor immune profiling predicts
response to anti-PD-1 therapy in human melanoma. J Clin Invest.
126:3447–3452. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Kim R, Keam B, Kim S, Kim M, Kim SH, Kim
JW, Kim YJ, Kim TM, Jeon YK, Kim DW, et al: Differences in tumor
microenvironments between primary lung tumors and brain metastases
in lung cancer patients: Therapeutic implications for immune
checkpoint inhibitors. BMC Cancer. 19:192019. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Chen DS and Mellman I: Elements of cancer
immunity and the cancer-immune set point. Nature. 541:321–330.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Kim CG, Jang M, Kim Y, Leem G, Kim KH, Lee
H, Kim TS, Choi SJ, Kim HD, Han JW, et al: VEGF-A drives
TOX-dependent T cell exhaustion in anti-PD-1-resistant
microsatellite stable colorectal cancers. Sci Immunol.
4:eaay05552019. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Ngiow SF, Young A, Jacquelot N, Yamazaki
T, Enot D, Zitvogel L and Smyth MJ: A threshold level of intratumor
CD8+ T-cell PD1 expression dictates therapeutic response to
Anti-PD1. Cancer Res. 75:3800–3811. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Davis RJ, Moore EC, Clavijo PE, Friedman
J, Cash H, Chen Z, Silvin C, Van Waes C and Allen C: Anti-PD-L1
efficacy Can Be enhanced by inhibition of myeloid-derived
suppressor cells with a selective inhibitor of PI3Kδ/γ. Cancer Res.
77:2607–2619. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Mao Y, Eissler N, Blanc KL, Johnsen JI,
Kogner P and Kiessling R: Targeting suppressive myeloid cells
potentiates checkpoint inhibitors to control spontaneous
neuroblastoma. Clin Cancer Res. 22:3849–3859. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Stone TW and Darlington LG: Endogenous
kynurenines as targets for drug discovery and development. Nat Rev
Drug Discov. 1:609–620. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
99
|
Llosa NJ, Cruise M, Tam A, Wicks EC,
Hechenbleikner EM, Taube JM, Blosser RL, Fan H, Wang H, Luber BS,
et al: The vigorous immune microenvironment of microsatellite
instable colon cancer is balanced by multiple counter-inhibitory
checkpoints. Cancer Discov. 5:43–51. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Higgs BW, Robbins PB, Blake-Haskins JA,
Zhu W, Morehouse C, Brohawn PZ, Rebelatto MC, Yao Y, Jin X, Shi L
and Ranade K: 15LBA High tumoral IFNγ mRNA, PD-L1 protein, and
combined IFNγ mRNA/PD-L1 protein expression associates with
response to durvalumab (anti-PD-L1) monotherapy in NSCLC patients.
Eur J Cancer. 51 (Suppl):S7172015. View Article : Google Scholar
|
|
101
|
Ascierto ML, McMiller TL, Berger AE,
Danilova L, Anders RA, Netto GJ, Xu H, Pritchard TS, Fan J, Cheadle
C, et al: The intratumoral balance between metabolic and
immunologic gene expression is associated with Anti-PD-1 response
in patients with renal cell carcinoma. Cancer Immunol Res.
4:726–733. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Francisco LM, Salinas VH, Brown KE,
Vanguri VK, Freeman GJ, Kuchroo VK and Sharpe AH: PD-L1 regulates
the development, maintenance, and function of induced regulatory T
cells. J Exp Med. 206:3015–3029. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Ding ZC, Lu X, Yu M, Lemos H, Huang L,
Chandler P, Liu K, Walters M, Krasinski A, Mack M, et al:
Immunosuppressive myeloid cells induced by chemotherapy attenuate
antitumor CD4+ T-cell responses through the PD-1-PD-L1 axis. Cancer
Res. 74:3441–3453. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Platten M, Wick W and Van den Eynde BJ:
Tryptophan catabolism in cancer: Beyond IDO and tryptophan
depletion. Cancer Res. 72:5435–5440. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Ayers M, Lunceford J, Nebozhyn M, Murphy
E, Loboda A, Kaufman DR, Albright A, Cheng JD, Kang SP, Shankaran
V, et al: IFN-γ-related mRNA profile predicts clinical response to
PD-1 blockade. J Clin Invest. 127:2930–2940. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Zhang X, Zeng Y, Qu Q, Zhu J, Liu Z, Ning
W, Zeng H, Zhang N, Du W, Chen C, et al: PD-L1 induced by IFN-γ
from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT
signaling pathways promoted progression of lung cancer. Int J Clin
Oncol. 22:1026–1033. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Quandt D, Jasinski-Bergner S, Muller U,
Schulze B and Seliger B: Synergistic effects of IL-4 and TNFα on
the induction of B7-H1 in renal cell carcinoma cells inhibiting
allogeneic T cell proliferation. J Transl Med. 12:1512014.
View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Ni XY, Sui HX, Liu Y, Ke SZ, Wang YN and
Gao FG: TGF-β of lung cancer microenvironment upregulates B7H1 and
GITRL expression in dendritic cells and is associated with
regulatory T cell generation. Oncol Rep. 28:615–621. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Rodriguez-Garcia M, Porichis F, de Jong
OG, Levi K, Diefenbach TJ, Lifson JD, Freeman GJ, Walker BD,
Kaufmann DE and Kavanagh DG: Expression of PD-L1 and PD-L2 on human
macrophages is up-regulated by HIV-1 and differentially modulated
by IL-10. J Leukoc Biol. 89:507–515. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Kondou R, Iizuka A, Nonomura C, Miyata H,
Ashizawa T, Nagashima T, Ohshima K, Urakami K, Kusuhara M,
Yamaguchi K, et al: Classification of tumor microenvironment immune
types based on immune response-associated gene expression. Int J
Oncol. 54:219–228. 2019.PubMed/NCBI
|
|
111
|
Spranger S, Spaapen RM, Zha Y, Williams J,
Meng Y, Ha TT and Gajewski TF: Up-regulation of PD-L1, IDO, and
T(regs) in the melanoma tumor microenvironment is driven by CD8(+)
T cells. Sci Transl Med. 5:200ra1162013. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Zhao J, Wen X, Tian L, Li T, Xu C, Wen X,
Melancon MP, Gupta S, Shen B, Peng W, et al: Irreversible
electroporation reverses resistance to immune checkpoint blockade
in pancreatic cancer. Nat Commun. 10:8992019. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Liu P, Zhao L, Pol J, Levesque S,
Petrazzuolo A, Pfirschke C, Engblom C, Rickelt S, Yamazaki T,
Iribarren K, et al: Crizotinib-induced immunogenic cell death in
non-small cell lung cancer. Nat Commun. 10:14862019. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Nikolich-Zugich J, Slifka MK and Messaoudi
I: The many important facets of T-cell repertoire diversity. Nat
Rev Immunol. 4:123–132. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Ruggiero E, Nicolay JP, Fronza R, Arens A,
Paruzynski A, Nowrouzi A, Urenden G, Lulay C, Schneider S, Goerdt
S, et al: High-resolution analysis of the human T-cell receptor
repertoire. Nat Commun. 6:80812015. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Zheng Y, Wang T, Tu X, Huang Y, Zhang H,
Tan D, Jiang W, Cai S, Zhao P, Song R, et al: Gut microbiome
affects the response to anti-PD-1 immunotherapy in patients with
hepatocellular carcinoma. J Immunother Cancer. 7:1932019.
View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Sunakawa Y, Inoue E, Matoba R, Kawakami H,
Sato Y, Nakajima TE, Muro K, Ichikawa W and Fujii M: DELIVER
(JACCRO GC-08) trial: Discover novel host-related immune-biomarkers
for nivolumab in advanced gastric cancer. Future Oncol.
15:2441–2447. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Matson V, Fessler J, Bao R, Chongsuwat T,
Zha Y, Alegre ML, Luke JJ and Gajewski TF: The commensal microbiome
is associated with anti-PD-1 efficacy in metastatic melanoma
patients. Science. 359:104–108. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Jin Y, Dong H, Xia L, Yang Y, Zhu Y, Shen
Y, Zheng H, Yao C, Wang Y and Lu S: The diversity of gut microbiome
is associated with favorable responses to anti-programmed death 1
immunotherapy in Chinese patients with NSCLC. J Thorac Oncol.
14:1378–1389. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Ivanov II and Littman DR: Modulation of
immune homeostasis by commensal bacteria. Curr Opin Microbiol.
14:106–114. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Sivan A, Corrales L, Hubert N, Williams
JB, Aquino-Michaels K, Earley ZM, Benyamin FW, Lei YM, Jabri B,
Alegre ML, et al: Commensal Bifidobacterium promotes antitumor
immunity and facilitates anti-PD-L1 efficacy. Science.
350:1084–1089. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Vetizou M, Pitt JM, Daillere R, Lepage P,
Waldschmitt N, Flament C, Rusakiewicz S, Routy B, Roberti MP, Duong
CP, et al: Anticancer immunotherapy by CTLA-4 blockade relies on
the gut microbiota. Science. 350:1079–1084. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Dong M, Meng Z, Kuerban K, Qi F, Liu J,
Wei Y, Wang Q, Jiang S, Feng M and Ye L: Diosgenin promotes
antitumor immunity and PD-1 antibody efficacy against melanoma by
regulating intestinal microbiota. Cell Death Dis. 9:10392018.
View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Weide B, Martens A, Hassel JC, Berking C,
Postow MA, Bisschop K, Simeone E, Mangana J, Schilling B, Di
Giacomo AM, et al: Baseline biomarkers for outcome of melanoma
patients treated with pembrolizumab. Clin Cancer Res. 22:5487–5496.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Zer A, Sung MR, Walia P, Khoja L, Maganti
M, Labbe C, Shepherd FA, Bradbury PA, Feld R, Liu G, et al:
Correlation of neutrophil to lymphocyte ratio and absolute
neutrophil count with outcomes with PD-1 axis inhibitors in
patients with advanced non-small-cell lung cancer. Clin Lung
Cancer. 19:426–434.e1. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Diem S, Kasenda B, Spain L, Martin-Liberal
J, Marconcini R, Gore M and Larkin J: Serum lactate dehydrogenase
as an early marker for outcome in patients treated with anti-PD-1
therapy in metastatic melanoma. Br J Cancer. 114:256–261. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Gibney GT, Kudchadkar RR, DeConti RC,
Thebeau MS, Czupryn MP, Tetteh L, Eysmans C, Richards A, Schell MJ,
Fisher KJ, et al: Safety, correlative markers, and clinical results
of adjuvant nivolumab in combination with vaccine in resected
high-risk metastatic melanoma. Clin Cancer Res. 21:712–720. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Niemeijer AN, Leung D, Huisman MC, Bahce
I, Hoekstra OS, van Dongen G, Boellaard R, Du S, Hayes W, Smith R,
et al: Whole body PD-1 and PD-L1 positron emission tomography in
patients with non-small-cell lung cancer. Nat Commun. 9:46642018.
View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Bensch F, van der Veen EL, Lub-de Hooge
MN, Jorritsma- Smit A, Boellaard R, Kok IC, Oosting SF, Schroder
CP, Hiltermann TJN, van der Wekken AJ, et al:
89Zr-atezolizumab imaging as a non-invasive approach to
assess clinical response to PD-L1 blockade in cancer. Nat Med.
24:1852–1858. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Sun R, Limkin EJ, Vakalopoulou M, Dercle
L, Champiat S, Han SR, Verlingue L, Brandao D, Lancia A, Ammari S,
et al: A radiomics approach to assess tumour-infiltrating CD8 cells
and response to anti-PD-1 or anti-PD-L1 immunotherapy: An imaging
biomarker, retrospective multicohort study. Lancet Oncol.
19:1180–1191. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Joyce JA and Fearon DT: T cell exclusion,
immune privilege, and the tumor microenvironment. Science.
348:74–80. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Kluger HM, Zito CR, Barr ML, Baine MK,
Chiang VL, Sznol M, Rimm DL, Chen L and Jilaveanu LB:
Characterization of PD-L1 expression and associated T-cell
infiltrates in metastatic melanoma samples from variable anatomic
sites. Clin Cancer Res. 21:3052–3060. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Rooney MS, Shukla SA, Wu CJ, Getz G and
Hacohen N: Molecular and genetic properties of tumors associated
with local immune cytolytic activity. Cell. 160:48–61. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Feng Z, Puri S, Moudgil T, Wood W, Hoyt
CC, Wang C, Urba WJ, Curti BD, Bifulco CB and Fox BA: Multispectral
imaging of formalin-fixed tissue predicts ability to generate
tumor-infiltrating lymphocytes from melanoma. J Immunother Cancer.
3:472015. View Article : Google Scholar : PubMed/NCBI
|
